Genfit SA (GNFT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GENFIT SA reported strong first half-year 2024 financial results, with €61.6 million in cash reserves and €59.0 million in revenue, bolstered by a €48.7 million milestone from U.S. sales of its PBC treatment, Iqirvo. The company anticipates additional European momentum with an expected €26.5 million milestone following Iqirvo’s anticipated pricing and reimbursement approval. GENFIT’s advancements in liver disease treatments and diagnostics, alongside positive U.S. market reception, position it optimistically for future developments.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.